NCT00875420

A Study to Evaluate the Effects of RAD1901 in the Treatment of Vasomotor Symptoms in Postmenopausal Women

A Randomized, Placebo-Controlled, Double-Blind, Parallel-Group, Phase 2, Multi-Center, Dose-Finding Study to Evaluate the Effects of RAD1901 in the Treatment of Vasomotor Symptoms in Postmenopausal Women

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 100 (actual)
• Sponsor: Radius Pharmaceuticals, Inc. · Industry
• Sex: Female
• Age: 40 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to determine whether RAD1901 is effective in decreasing hot flashes in postmenopausal women.

Conditions

• Hot Flashes

Interventions

Type	Name	Description
DRUG	RAD1901	10 mg Oral once a day for 28 days.
DRUG	RAD1901	25 mg Oral once a day for 28 days
DRUG	RAD1901	50 mg Oral once a day for 28 days.
DRUG	RAD1901	100 mg Oral once a day for 28 days
DRUG	Placebo	Placebo Oral once a day for 28 days

Timeline

• Start date: 2009-03-01
• Primary completion: 2010-01-01
• Completion: 2010-04-01
• First posted: 2009-04-03
• Last updated: 2018-09-26
• Results posted: 2012-03-26

Locations

1 site across 1 country: United States